Literature DB >> 20959653

Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics.

Damien Hansra1, Naomi Montague, Alexandra Stefanovic, Ikechukwu Akunyili, Arash Harzand, Yasodha Natkunam, Margarita de la Ossa, Gerald E Byrne, Izidore S Lossos.   

Abstract

Plasmablastic lymphoma (PBL), initially characterized as an aggressive lymphoma arising in the jaw and oral mucosa in HIV-infected patients, was recently reported to occur with extraoral manifestations, heterogeneous histologic findings, and variable association with immunodeficiency states. We reviewed clinical, morphologic, and immunophenotypic features of 13 cases of PBL to determine whether these different subtypes represent distinct morphologic and clinical entities. Two distinct subtypes of PBL were identified and classified as oral and extraoral PBL. The oral PBLs were strongly associated with HIV infection and commonly demonstrated plasmablastic morphologic features without plasmacytic differentiation. Extraoral PBLs tended to occur in patients with underlying non-HIV-related immunosuppression and universally demonstrated plasmacytic differentiation. The patients with oral PBL demonstrated better overall survival compared with patients with extraoral PBL (P = .02). Our findings suggest that PBL with oral and extraoral manifestation represent 2 distinct clinicopathologic entities.

Entities:  

Mesh:

Year:  2010        PMID: 20959653     DOI: 10.1309/AJCPJH6KEUSECQLU

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  15 in total

1.  Extensive maxillofacial plasmablastic lymphoma in an immunocompetent patient.

Authors:  Zacharias Vourexakis; Pavel Dulguerov
Journal:  BMJ Case Rep       Date:  2014-08-07

2.  Oral lesion as the primary diagnosis of non-Hodgkin's lymphoma: a 20-year experience from an oral pathology service and review of the literature.

Authors:  Natália Kusuke; Marcos Custódio; Suzana C O M de Sousa
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-08       Impact factor: 2.503

Review 3.  Newly emerging therapies targeting viral-related lymphomas.

Authors:  Juan Carlos Ramos; Izidore S Lossos
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 4.  Aggressive B-cell lymphomas: how many categories do we need?

Authors:  Jonathan W Said
Journal:  Mod Pathol       Date:  2012-11-16       Impact factor: 7.842

Review 5.  Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review.

Authors:  Lynette Luria; Johnny Nguyen; Jun Zhou; Michael Jaglal; Lubomir Sokol; Jane L Messina; Domenico Coppola; Ling Zhang
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

6.  Plasmablastic lymphoma of the stomach with C-MYC rearrangement in an immunocompetent young adult: a case report.

Authors:  Xin Huang; Yanping Zhang; Zifen Gao
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

Review 7.  Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.

Authors:  Ghaleb Elyamany; Eman Al Mussaed; Ali Matar Alzahrani
Journal:  Adv Hematol       Date:  2015-08-18

8.  Cutaneous plasmablastic lymphoma in an immunocompetent patient with long-term pyrimethamine use for essential thrombocythemia: a case report and literature review.

Authors:  Ing Soo Tiong; Magreet Strauss; Michael B Y Lau; Shingirai Chiruka
Journal:  Case Rep Hematol       Date:  2013-02-06

9.  An Aggressive Plasmablastic Lymphoma of the Oral Cavity as Primary Manifestation of Acquired Immunodeficiency Syndrome: Case Report and Literature Review.

Authors:  Marcelo Corti; Gonzalo Minué; Ana Campitelli; Marina Narbaitz; Leonardo Gilardi
Journal:  Int Arch Otorhinolaryngol       Date:  2015-01-08

10.  A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report.

Authors:  Makoto Hirosawa; Hiroaki Morimoto; Ryo Shibuya; Shohei Shimajiri; Junichi Tsukada
Journal:  Biomark Res       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.